European Commission
European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC
The agent is approved for non-small cell lung cancer patients in Europe whose tumors harbor METex14 skipping and who received prior immunotherapy and/or chemo.
European Commission Approves Keytruda in Early-Stage Triple-Negative Breast Cancer
The approval in Europe follows the FDA's approval for the same indication last year based on data from the KEYNOTE-522 trial.
Novartis Nabs European Approval for Kymriah in Follicular Lymphoma
The European Commission approved the autologous CAR T-cell therapy for relapsed or refractory follicular lymphoma patients after two or more prior treatments.
Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors
European regulators approved the agent for PD-L1-positive cervical cancer and for five tumor types defined by high microsatellite instability or DNA mismatch repair deficiency.
EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation
The European Commission will review the committee's recommendation and decide whether to approve the MET inhibitor for this indication in Europe.